Author:
Lüthi François,Pless Miklos,Leyvraz Serge,Biedermann Beat,Müller Emilie,Hermann Richard,Monnerat Christian
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. The NCCN Cancer- and Chemotherapy-Induced Anemia Clinical Practice Guideline in Oncology (Version 3.2009).© 2008 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org . Accessed [November 18, 2008]. To view the most recent and complete version of the guideline, go online to www.nccn.org
2. Aapro MS, Link H (2008) September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl 3):33–36
3. Arcasoy MO (2008) The non-haematopoietic biological effects of erythropoietin. Br J Haematol 141:14–31
4. Auerbach M, Ballard H, Trout JR, McIlwain M, Ackerman A, Bahrain H, Balan S, Barker L, Rana J (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22:1301–1307
5. Bamias A, Aravantinos G, Kalofonos C, Timotheadou N, Siafaka V, Vlahou I, Janinis D, Pectasides D, Pavlidis N, Fountzilas G (2003) Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human Erythropoietin (rHuEpo): a prospective, open label, randomized trial by the Hellenic Cooperative Oncology Group. Oncology 64:102–110